TY - CHAP
T1 - Tau PET Imaging
AU - Higuchi, Makoto
N1 - Publisher Copyright:
© Springer Nature Singapore Pte Ltd. 2019.
PY - 2019
Y1 - 2019
N2 - The deposition of fibrillar tau aggregates has been implicated in Alzheimer’s disease (AD) and allied neurodegenerative disorders collectively referred to as tauopathies. Growing non-clinical and clinical evidence has supported intimate links between tau fibrillogenesis and neuronal deteriorations, rationalizing the development of imaging agents for tau fibrils to gain etiological insights into tauopathies and to facilitate diagnostic and therapeutic approaches to these diseases. Radiochemicals derived from three major chemotypes were initially applied to positron emission tomography (PET) studies of human subjects, demonstrating their utility for capturing AD-type tau deposits with reasonably high contrast. Meanwhile, these tracers suffered substantial off-target binding in the brain and did not offer sensitive detection of tau lesions in a large proportion of non-AD tauopathies. To overcome such drawbacks, ‘second-generation’ tau PET probes have been generated and examined in clinical settings. These tracers have enabled specific assays of AD tau pathologies, and a novel radiocompound developed by our research group has been shown to produce high contrasts for AD and non-AD tau aggregates, potentially allowing diagnostic evaluations of diverse tauopathies on an individual basis.
AB - The deposition of fibrillar tau aggregates has been implicated in Alzheimer’s disease (AD) and allied neurodegenerative disorders collectively referred to as tauopathies. Growing non-clinical and clinical evidence has supported intimate links between tau fibrillogenesis and neuronal deteriorations, rationalizing the development of imaging agents for tau fibrils to gain etiological insights into tauopathies and to facilitate diagnostic and therapeutic approaches to these diseases. Radiochemicals derived from three major chemotypes were initially applied to positron emission tomography (PET) studies of human subjects, demonstrating their utility for capturing AD-type tau deposits with reasonably high contrast. Meanwhile, these tracers suffered substantial off-target binding in the brain and did not offer sensitive detection of tau lesions in a large proportion of non-AD tauopathies. To overcome such drawbacks, ‘second-generation’ tau PET probes have been generated and examined in clinical settings. These tracers have enabled specific assays of AD tau pathologies, and a novel radiocompound developed by our research group has been shown to produce high contrasts for AD and non-AD tau aggregates, potentially allowing diagnostic evaluations of diverse tauopathies on an individual basis.
UR - http://www.scopus.com/inward/record.url?scp=85079914980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079914980&partnerID=8YFLogxK
U2 - 10.1007/978-981-32-9358-8_18
DO - 10.1007/978-981-32-9358-8_18
M3 - Chapter
C2 - 32096041
AN - SCOPUS:85079914980
T3 - Advances in Experimental Medicine and Biology
SP - 217
EP - 230
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -